Editas Medicine Announces Second Quarter 2017 Results and Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Grand Canyon Education places CFO on leave amid stock trade probe
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
Editas Medicine (EDIT) Tops Q2 EPS by 6c
August 9, 2017 4:04 PM EDTEditas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.4 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More